Literature DB >> 8161775

Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.

A Bedi1, B A Zehnbauer, J P Barber, S J Sharkis, R J Jones.   

Abstract

BCR-ABL expression is presumed to effect clonal expansion in chronic myeloid leukemia (CML) by deregulation of cell proliferation. However, most studies have found that relative rates of cell proliferation are not increased in CML. Moreover, we found that CML progenitors display a normal proliferative response to growth factors and do not manifest greater proliferative potential than normal progenitors. Growth of malignancies depends on an imbalance between the rate of cell production and the rate of cell death. We found that BCR-ABL expression inappropriately prolongs the growth factor-independent survival of CML myeloid progenitors and granulocytes by inhibiting apoptosis, a genetically programmed process of active cell death; inhibition of BCR-ABL expression by antisense oligonucleotides reversed the suppression of apoptosis as well as the enhancement of survival. The decreased rate of programmed cell death appears to be the primary mechanism by which BCR-ABL effects expansion of the leukemic clone in CML.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8161775

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  81 in total

Review 1.  Biological consequences of the BCR/ABL fusion gene in humans and mice.

Authors:  M Y Gordon
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

Review 2.  Molecular pathways to CML stem cells.

Authors:  Kristen N Rice; Catriona H M Jamieson
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

3.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

4.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 6.  Treatment of chronic myelogenous leukaemia.

Authors:  B Simonsson
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

Authors:  M Y Gordon; S B Marley; J L Lewis; R J Davidson; D X Nguyen; F H Grand; T A Amos; J M Goldman
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

Review 9.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 10.  Chronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase.

Authors:  Vito Michele Lauta
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.